Filing Details
- Accession Number:
- 0000899243-20-016664
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-06-16 17:03:33
- Reporting Period:
- 2020-06-12
- Accepted Time:
- 2020-06-16 17:03:33
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1576263 | Mirati Therapeutics Inc. | MRTX | Pharmaceutical Preparations (2834) | 462693615 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1642355 | Ltd. Braslyn | Cay House, Ep Taylor Drive N7776 Lyford Cay New Providence C5 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2020-06-12 | 600,000 | $69.00 | 2,535,966 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2020-06-12 | 600,006 | $0.00 | 3,135,972 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-06-12 | 6 | $72.80 | 3,135,966 | No | 4 | F | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | F | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Warrant (right to purchase) | Disposition | 2020-06-12 | 600,006 | $5.60 | 600,006 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
3,990,420 | 2017-01-06 | No | 4 | M | Direct |
Footnotes
- The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 9.99% of the issuer's common stock.